Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Core Insights - Myriad Genetics, Inc. has appointed Brian Donnelly as chief commercial officer, effective May 1, 2025, to enhance its leadership team and drive growth [1][2][3] Company Overview - Myriad Genetics is a leader in molecular diagnostics testing and precision medicine, focusing on advancing health and well-being through innovative molecular tests that assess disease risk and guide treatment decisions [4] Leadership Appointment - Brian Donnelly brings over 20 years of experience in healthcare, diagnostics, and medical technology, with a strong track record in managing multi-billion-dollar P&Ls and driving growth through innovative strategies [2][3] - Donnelly has held senior roles at notable organizations such as Ancestry, Amazon, and Illumina, where he successfully drove business growth across global markets [3] Strategic Vision - The incoming president and CEO of Myriad Genetics, Sam Raha, emphasized Donnelly's strategic vision and operational excellence, highlighting his role in scaling the business and accelerating product adoption [3] - Donnelly expressed enthusiasm for joining Myriad Genetics, focusing on expanding the company's impact and fostering innovation while adhering to its mission [3]